Most Searched
Originally published November 17, 2026
Last updated November 17, 2026
Reading Time: 4 minutes
Search more articles
News & Magazine
Topics
Since 2001, neurologists have used the McDonald criteria to guide diagnoses of multiple sclerosis (MS), an autoimmune disease in which demyelination of brain, spinal cord and optic nerve cells triggers progressive neurological impairment and brain atrophy.
The International Advisory Committee on Clinical Trials in Multiple Sclerosis — a global expert body cosponsored by the National Multiple Sclerosis Society (NMSS) and the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) — updates these criteria every five to seven years as diagnostic technology and understanding of the disease advance.
Last year saw the release of the latest revisions. “They allow for an earlier and more accurate diagnosis, which will help clinicians make better decisions about treatment and hopefully lead to less disability over time,” says Lilyana Amezcua, MD, an elected member of the advisory committee and director of the USC MS and Neuroimmunology Center, part of USC Neurosciences and Keck Medicine of USC.
The revisions comprise the following major updates:
In the past, when incidental imaging revealed brain lesions characteristic of MS, patients still had to experience an actual clinical event — such as optic neuritis or transverse myelitis — to merit diagnosis. “But sometimes patients present atypically with symptoms not specific to a clinical event,” Amezcua notes, “or they may have other symptoms entirely.”
The criteria now permit diagnosis and treatment for patients with MRI findings that indicate radiologically isolated syndrome (RIS) — central nervous system demyelination consistent with MS — or who test for specific spinal-fluid biomarkers whether or not they’ve yet had a physical attack. “Even without that clinical event,” Amezcua says, “we can determine that this isn’t just probable or possible MS, but is MS. And the patient can benefit from treatment.”
A core criterion had also been to establish dissemination in time (DIT) of central nervous system damage: A patient would have to experience multiple clinical attacks separated in time or receive a follow-up MRI corroborating previous suggestive results.
The updates eliminate that requirement and now accept the presence of paramagnetic rim lesions (PRLs) on a baseline MRI or a single positive test for kappa free-light chains (kFLCs) in the spinal fluid as evidence of active inflammation and progressive disease.
This gives clinicians the green light to initiate care without delay. As Amezcua observes, “In the past, you could wait up to 10 years before an actual diagnosis. But the longer you wait, the higher the risk of a new clinical event, and that’s associated with new scars and accumulating disability.”
Just as earlier criteria required that symptoms display dissemination in time, they also mandated that signs of immune-mediated damage show dissemination in space (DIS) across four independent locations in the central nervous system. The 2024 revisions now add a fifth: the optic nerve.
Amezcua was instrumental in bringing this issue to the fore, having coauthored a retrospective study showing that Hispanic MS patients are twice as likely to present with optic neuritis as are their white counterparts.
“This paper gives evidence that inclusion of optic neuritis in DIS improved the overall performance of the earlier criteria among Hispanic populations,” she says, adding that current diagnostic modalities like MRI, optical coherence tomography (OCT) and visual evoked potentials (VEPs) can help clinicians identify signs of optic-nerve involvement. Meanwhile, tests for antibodies like AQP4-IgG and MOG-IgG serve to rule out lookalike conditions such as neuromyelitis optica (NMO) and MOG-associated disease (MOGAD).
Oligoclonal bands (OCBs) in the cerebrospinal fluid were accepted as a marker of MS damage in earlier revisions to the criteria; new revisions include kFLCs as an equivalent, but more cost-effective, biomarker, as well. “If you were having trouble getting oligoclonal bands,” Amezcua says, “this gives you more options to integrate in making that diagnosis much earlier and more accurately.”
And given improvements in MRI technology, the 2024 criteria now accept both PRLs and the central vein sign (CVS) as high-specificity imaging biomarkers of MS-related damage. “We have new tools and sequences that help us better understand that these lesions are, in fact, demyelinating,” Amezcua emphasizes, “and they’ve been very useful in making that diagnosis sooner.”
However, she adds, because testing for CVS or PRLs isn’t always widely available, “You may need to go to an academic center to get those sequences or to find specialists able to read those types of criteria.”
Finally, the new criteria include measures to curtail potential misdiagnoses in certain populations. For example, given that older brains and brains with vascular disease can present with lesions similar to those common in MS, the criteria advise clinicians to look for specific spinal-fluid markers, spinal-cord lesions or a positive CVS to confirm MS in patients aged 50 and older and in those with vascular disease.
And for children younger than 12 who present with an initial demyelinating episode, the criteria require MOG-IgG testing to rule out MOGAD.
Amezcua notes that only 2% to 5% of MS cases begin before age 18, with most appearing between age 20 and 40. But as diagnostic tools improve and the McDonald criteria embrace them, case numbers in the young may climb. But if those diagnoses lead to better care sooner, Amezcua believes it’s a win. “That’s been the evolution of the research in the last 20 years: Why should we wait?”
Share